Cargando…
Retigabine holds K(V)7 channels open and stabilizes the resting potential
The anticonvulsant Retigabine is a K(V)7 channel agonist used to treat hyperexcitability disorders in humans. Retigabine shifts the voltage dependence for activation of the heteromeric K(V)7.2/K(V)7.3 channel to more negative potentials, thus facilitating activation. Although the molecular mechanism...
Autores principales: | Corbin-Leftwich, Aaron, Mossadeq, Sayeed M., Ha, Junghoon, Ruchala, Iwona, Le, Audrey Han Ngoc, Villalba-Galea, Carlos A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772374/ https://www.ncbi.nlm.nih.gov/pubmed/26880756 http://dx.doi.org/10.1085/jgp.201511517 |
Ejemplares similares
-
Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine
por: Barrese, Vincenzo, et al.
Publicado: (2010) -
Molecular Insights Into Binding and Activation of the Human KCNQ2 Channel by Retigabine
por: Garofalo, Barbara, et al.
Publicado: (2022) -
The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker
por: Su, Tzu-Rong, et al.
Publicado: (2012) -
Electro-mechanical coupling of KCNQ channels is a target of epilepsy-associated mutations and retigabine
por: Yang, Nien-Du, et al.
Publicado: (2022) -
One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels
por: Yau, Michael C., et al.
Publicado: (2018)